首页> 外文会议>IEEE International Conference on Nanotechnology >Ginsenoside Rg1 Nanophytosome synthesis and their characterization: An initiative towards the treatment of Amyotrophic Lateral Sclerosis
【24h】

Ginsenoside Rg1 Nanophytosome synthesis and their characterization: An initiative towards the treatment of Amyotrophic Lateral Sclerosis

机译:人参皂甙RG1纳米细胞体合成及其表征:对治疗肌营养侧面硬化症的举例

获取原文

摘要

Amyotrophic lateral sclerosis is a devastating neurodegenerative disease that affects the brain and spinal cord of healthy adults. The disease progresses rapidly and is fatal, leaving patients paralyzed and unable to breathe. The cause of the disease and its progression remains poorly understood. Currently, there are no known cure or effective treatment available for ALS. But with the advances in medicine and technology, there has been a huge rise in data produced. The present study is focused on synthesis and characterization of Nanophytosomes (NP) to improve the bioavailability and efficacy of Ginsenoside Rg1 compound. The nanoparticles were visualized by SEM and analyzed by Fourier Transform Infrared Spectroscopy for the type of interactions holding the components together in the NP. The size of the NP was in the range of 180 to 195nm. A comparative antimicrobial assay against strains of E.coli for NP and Ginsenoside Rg1 showed positive results for NP with increasing CFUs of E.coli while Ginsenoside Rg1 showed results only at lower CFUs of the Bacteria. Dispersion studies suggested that the NP had a maximum release rate of the drug at about 4 hours. This suggests the stability and sustained release property of the NP as compared to Ginsenoside Rgl which acts immediately on the target. Antioxidant's property of the NP was compared with Ginsenoside Rg1 by testing scavenging potential through assays such as SOD, NO and DPPH. The antioxidant activity was concentration dependent and the anti-oxidative properties of NP was found in the close range with that of Ginsenoside Rg1 compound. NP could possess antioxidative properties which could last longer than the compound alone when compared. The current technology thus could be a boon to the treatment of chronic diseases like ALS, Parkinson's Disease, AD as it improves the bioavailability and efficacy of the drug it encapsulates.
机译:肌营养的外侧硬化是一种破坏性的神经变性疾病,影响健康成年人的脑和脊髓。这种疾病迅速进行,致命,让患者瘫痪,无法呼吸。这种疾病的原因及其进展仍然难以理解。目前,ALS没有可用的固化或有效治疗。但随着医学和技术的进步,产生了巨大的数据崛起。本研究专注于纳米细胞体(NP)的合成和表征,以改善人参皂苷RG1化合物的生物利用度和功效。通过SEM通过SEM进行可视化纳米颗粒,并通过傅里叶变换红外光谱分析,用于将组分保持在NP中的相互作用。 NP的大小在180至195nm的范围内。对于NP和人参皂甙RG1,对大肠杆菌菌株的比较抗微生物测定显示NP的阳性结果随着大肠杆菌的增加,而人参皂甙RG1仅在细菌的较低CFU下显示结果。分散研究表明,NP在约4小时内具有最大释放速率。这表明与人参皂苷RGL相比,NP的稳定性和持续的释放性能,其立即在目标上起作用。通过测定诸如SOD,NO和DPPH等测定,将抗氧化剂与人参皂甙RG1进行比较。抗氧化活性浓度依赖性,并且在近距离中发现NP的抗氧化性能RG1化合物的近距离。 NP可以具有抗氧化性能,其在比较时可以持续比化合物更长。因此,目前的技术可能是一种营养慢性疾病,如ALS,帕金森病,广告,因为它改善了它封装的药物的生物利用度和功效。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号